Tatyana Simak

Learn More
BACKGROUND Russia is a high tuberculosis (TB) burden country with a high prevalence of multidrug resistant tuberculosis (MDRTB). Molecular assays for detection of MDRTB on clinical specimens are not widely available in Russia. RESULTS We performed an evaluation of the GenoType MTBDRplus assay (HAIN Lifescience GmbH, Germany) on a total of 168 sputum(More)
OBJECTIVE To analyse the feasibility, cost and performance of rapid tuberculosis (TB) molecular and culture systems, in a high multidrug-resistant TB (MDR TB) middle-income region (Samara, Russia) and provide evidence for WHO policy change. METHODS Performance and cost evaluation was conducted to compare the BACTEC MGIT 960 system for culture and drug(More)
Background. Russia is a high tuberculosis (TB) burden country with a high prevalence of multidrug resistant tuberculosis (MDRTB). Molecular assays for detection of MDRTB on clinical specimens are not widely available in Russia. Results. We performed an evaluation of the GenoType® MTBDRplus assay (HAIN Lifescience GmbH, Germany) on a total of 168 sputum(More)
The paper gives the results of a demonstration project to introduce a test for drug sensitivity to second-line antituberculous agents for patients with multidrug-resistant (MDR) tuberculosis at a routine large Russian laboratory. Two hundred and thirty MDR isolates were examined; of them 8.7% had extreme drug resistance. The cost of this test was estimated(More)
  • 1